Share on StockTwits

Shares of DexCom (NASDAQ:DXCM) have earned an average rating of “Hold” from the thirteen ratings firms that are currently covering the company, StockRatingsNetwork.com reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $41.00.

A number of research firms have recently commented on DXCM. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock.

In other DexCom news, CEO Terrance H. Gregg sold 23,893 shares of the stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $44.36, for a total transaction of $1,059,893.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

DexCom (NASDAQ:DXCM) opened at 44.08 on Wednesday. DexCom has a 52-week low of $25.49 and a 52-week high of $49.83. The stock’s 50-day moving average is $39.7 and its 200-day moving average is $38.9. The company’s market cap is $3.327 billion.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The company’s revenue for the quarter was up 64.2% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.32 earnings per share for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.